Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.
In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:
Presenters:
Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
See full program:
https://bit.ly/3OQ6634